[Totally subcutaneous cardioverter-defibrillator (S-ICD®) : recent experience and future perspectives].

The implantable cardioverter defibrillator (ICD) is an established therapy for patients at risk of sudden cardiac death. Nevertheless the endocardial electrode in conventional systems plays a major role in long-term complications (difficult removal, risk of endocarditis, etc.). The totally subcutaneous ICD (S-ICD®, Cameron Health, San Clemente, CA, USA) represents a new and particularly significant development in ICD therapy which, since it requires no electrode in or on the heart, results in significantly fewer perioperative and long-term complications (e.g., thromboembolism and endocarditis risk). Although we see an indication for primary and secondary prevention, patients need to be informed about the limited data from randomized trials with the S-ICD®. As there is no permanent pacing option, patients in whom a pacemaker is indicated are not appropriate candidates for S-ICD®. In addition, patients with ventricular tachycardias that can be terminated by antitachycardic pacing are not recommended for the device. In the present article, we report our initial experience with the 18 patients implanted with the S-ICD® to date, comment on the available studies and offer a critical perspective.